Kovack Advisors Inc. Sells 2,806 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Kovack Advisors Inc. lowered its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 4.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,866 shares of the specialty pharmaceutical company’s stock after selling 2,806 shares during the period. Kovack Advisors Inc. owned approximately 0.09% of Jazz Pharmaceuticals worth $6,757,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the business. CWA Asset Management Group LLC bought a new position in shares of Jazz Pharmaceuticals in the third quarter worth approximately $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Jazz Pharmaceuticals by 135.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after buying an additional 100,112 shares in the last quarter. Centre Asset Management LLC bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth approximately $9,335,000. Moloney Securities Asset Management LLC bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth approximately $464,000. Finally, Pacer Advisors Inc. raised its holdings in shares of Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after purchasing an additional 278,465 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the transaction, the chief executive officer now owns 425,525 shares in the company, valued at $52,522,550.75. This trade represents a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 5,053 shares of company stock worth $617,442 over the last 90 days. 4.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on JAZZ shares. JPMorgan Chase & Co. boosted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday. Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and boosted their price objective for the company from $140.00 to $150.00 in a report on Wednesday. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $140.00 to $175.00 in a report on Thursday, December 12th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $130.00 to $170.00 in a report on Thursday, February 13th. Finally, Barclays reaffirmed an “overweight” rating on shares of Jazz Pharmaceuticals in a report on Thursday. Two equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $182.47.

Jazz Pharmaceuticals Price Performance

JAZZ stock opened at $144.17 on Thursday. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The company has a fifty day simple moving average of $125.42 and a two-hundred day simple moving average of $118.44. The firm has a market capitalization of $8.72 billion, a P/E ratio of 20.31, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.